Lupin receives FDA approval to market generic antidepressant drug
Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
India-based Lupin Ltd. received U.S. FDA approval to market its Paroxetin extended release tablets, a generic of Apotex Technologies Inc.'s Paxil CR tablets.
The drug is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.
Lupin will begin promoting the product soon.